Cresanto Global Ltd.

RAYLA

₹3.48

0% (0)

Market Cap

₹1 Cr.

P/E

0.00

Key Ratios

Edit Ratio's

Market cap

1.00 Cr

Prom Holding

32.27 %

ROE (%)

4.22

ROCE (%)

-419.84

Div Yield (%)

Sales

OPM (%)

Debt to Equity

Edit Ratio's

About

Raymed Labs Ltd is a pharmaceutical company that specializes in manufacturing a wide range of … Read more

Low

52W Range

High

Timeline

Key company specific updates

Company Timeline

Custom financial statementNew

Edit rows

In Rs. Cr.	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025

In Rs. Cr.	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Balance sheet
Net Block	0.19	0.19	0.18	0.17	0.17	0.16	0.16	0.15	0.15	—
Shareholders Funds	-1.77	-1.82	-1.87	-1.93	-1.98	-2.05	-2.13	-2.31	-2.41	-2.59
Profit & Loss
Operating Profit	—	—	—	-0.03	-0.06	-0.07	-0.08	-0.19	-0.10	—
Net Sales	—	—	—	—	—	—	—	—	—	—
Cash flow
Cash from Operating Activity	0.01	0.00	0.00	0.00	-0.00	0.00	-2.21	-0.16	-0.06	-0.59
Net Capex (est)	—	—	—	—	—	—	—	—	—	-0.65
Ratios
ROCE (%)	—	—	—	1.25	2.81	3.35	-113	-262	-420	—
ROE (%)	—	—	—	2.78	2.81	3.35	3.84	7.41	4.22	—

Forensics

6 Yes

Positive for this company

1 Neutral

Neutral for this company

3 No

Negative for this company

7 No Data

Insufficient data to analyse

Accounting & Shareholding

Depreciation Effect

Depreciation accounting is not leading to increase in profits
Pledge

Promoters have not pledged a significant portion of their holding
Retail Holding

Retail has been selling the stock which is usually a good time to buy
Promoter Holding

Promoter has not sold any shares in the last 90 days
Revenue Recognition

Unable to calculate due to limited data
Contingent Liabilities

Unable to calculate due to limited data
Other Income

Unable to calculate due to limited data

Price & Performance

Working Capital

Working capital of the company seems to be under control
Debt

Company should not have issues servicing its debt
Balance Sheet Strength

Balance sheet of the company is strong. it shouldnt have solvency or liquidity issues
Capex vs ROCE

Roce of the company has decreased even without significant capex
Margin Stability

Margins of the company are volatile
ROCE Strength

Roce of the company is not consistently strong
ROE

Unable to calculate due to limited data
Current vs Historic Valuation

Unable to calculate due to limited data
Share price

Unable to calculate due to limited data
Sales Growth

Unable to calculate due to limited data

Revenue mix

Product Wise Break-Up

Peer Comparison

Peer Name	Latest Price	PE	Market cap(Cr)	Prom Holding(%)	YoY Qtly Sales(%)	ROCE (%)	ROE (%)
Cresanto Global	3.48	0.00	1	32.27	—	-419.84	4.22
Hemo Organic	11.25	23.92	4	16.85	10,872.73	-31.07	83.73
Zyden Gentec	0.87	0.00	5	—	—	-7.2	-63
MPS Pharmaa	2.87	0.00	5	35.89	—	-38.83	-42.21
Fabino Enterprises	30.8	106.03	6	56.82	—	1.6	0.86
Kobo Biotech	2.35	0.00	6	44.95	—	6.13	4.34
Ganga Pharma.	13.32	82.59	6	56.02	74.22	3.33	0.66
Senbo Industries	7	0.00	8	56.38	—	—	—

FAQs on Cresanto Global Ltd. Business

What does Cresanto Global do?

Raymed Labs Ltd specializes in the manufacturing of a diverse range of pharmaceutical products including antibiotics, anti-inflammatories, and other medications for both human and veterinary use.

Who are the competitors of Cresanto Global?

Cresanto Global major competitors are Hemo Organic, Zyden Gentec, MPS Pharmaa, Kobo Biotech, Ganga Pharma., Fabino Enterprises, Senbo Industries.
Market Cap of Cresanto Global is ₹1 Crs.
While the median market cap of its peers are ₹6 Crs.

Is Cresanto Global financially stable compared to its competitors?

Cresanto Global seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

View FAQ's On Shareprice

Company Filing

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release
Investor Presentation
Conference Call
Conference Call SummaryCon Call Summary Powered by Gemini

Discussions & Analysis

Ideas Dashboard

Timeline

Watchlist

Portfolio

Alerts

Research

Stock Screener

Market

Raw Material

Cresanto Global Ltd.

Cresanto Global Ltd.

Key Ratios

About

Timeline

Company Timeline

6 Yes

1 Neutral

3 No

7 No Data

Accounting & Shareholding

Depreciation Effect

Pledge

Retail Holding

Promoter Holding

Revenue Recognition

Contingent Liabilities

Other Income

Price & Performance

Working Capital

Debt

Balance Sheet Strength

Capex vs ROCE

Margin Stability

ROCE Strength

ROE

Current vs Historic Valuation

Share price

Sales Growth

Product Wise Break-Up

UNLOCK PREMIUM

What does Cresanto Global do?

Who are the competitors of Cresanto Global?

Is Cresanto Global financially stable compared to its competitors?

SIGN UP FOR FREE